Skip to main content
Clinical Trials/NCT05266859
NCT05266859CompletedPhase 2

Comparison of Efficacy of Platelet-rich Fibrin, Mineral Trioxide Aggregate and Calcium Hydroxide as Pulpotomy Medicaments in Permanent Teeth With Irreversible Pulpitis

Liaquat College of Medicine and Dentostry1 site in 1 country114 target enrollmentStarted: August 28, 2019Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Phase 2
Status
Completed
Sponsor
Enrollment
114
Locations
1
Primary Endpoint
Clinical Success or Failure

Study Overview

Brief Summary

Of all the various pulpotomy medicaments that have been studied till to date, three agents have been selected for this study to compare their efficacy. CH being the control, MTA being one of the most recommended biomaterial and PRF that in addition to being a biomaterial is an autologous agent. Uptil now there have been no prospective trials using these three pulpotomy agents in mature permanent teeth with irreversible pulpitis in our part of the world and even the international studies that have been done utilized different methodologies with no unanimous conclusion. This is the reason that at present this treatment regime (pulpotomy) showing better perspectives cannot be presented with confidence as a predictable treatment option to the patients with irreversible pulpitis. By virtue of this study this challenge is being undertaken.

Hypothesis:

ALTERNATE HYPOTHESIS There is a difference between the efficacy of the PRF, MTA and CH when used as pulpotomy medicaments in mature permanent teeth with irreversible pulpitis NULL HPOTHESIS There is no difference in efficacy of the PRF, MTA and CH when used as pulpotomy medicaments in mature permanent teeth with irreversible pulpitis

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double (Participant, Outcomes Assessor)

Eligibility Criteria

Ages
10 Years to 70 Years (Child, Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Patients with permanent teeth with completely formed roots diagnosed with irreversible pulpitis i.e. showing signs and symptoms as spontaneous, lingering pain initiated by hot and cold stimulus and /or radiating. Pulp being exposed or near to exposure by caries or alternatively by trauma.

Exclusion Criteria

  • •CLINICALLY Teeth with
  • •Necrotic pulp
  • •History of swelling, abscess , fistula and/ or sinus tract
  • •Doubtful restorability as indicated by over all Dental Practicality Index- (DPI) > 2 (Dawood and Patel 2017) will be excluded
  • •Periodontal disease
  • •Uncontrolled bleeding (more that 10 mins.) of pulp after removal of inflamed part.
  • •No bleeding of pulp at all after access into pulp RADIOGRAPHICALLY (with the use of periapical radiographs) Teeth with
  • •Internal/ external pathologic root resorption
  • •Pulp canal obliteration
  • •Periapical / furcal radiolucency
  • •Resorbed roots.
  • •Crestal bone loss Generally patients
  • •With systemic diseases, bleeding disorders, physical or mental disability, pregnant or nursing.
  • •On opioid or steroid therapy or anticoagulants and/or on any kind of antibiotics.
  • •Who have gone through some previous treatment for the same tooth other than filling.

Arms & Interventions

Group III- PRF (Experimental)

Experimental

Group III will receive PRF. PRF is platelet-rich fibrin that is a biocompatible product derived from patient's own blood. It is formed by centrifugation of the blood of the patient. It provides the growth factors and promotes regeneration of the pulp

Intervention: PRF (Other)

Group II- MTA (Experimental)

Experimental

Group II will receive MTA (Mineral Trioxide Aggregate). MTA is a calcium silicate based highly biocompatible material that is commonly used for pulpotomies in deciduous teeth along with the regenerative procedures in permanent and deciduous teeth

Intervention: MTA (Other)

Group I- Calcium hydroxide (Control)

Active Comparator

Group I will receive Calcium hydroxide . Calcium hydroxide is a gold standard medicament for the pulpotomy in deciduous teeth. It has antibacterial effects and widely used to disinfect the root canals.

This group will act as a control

Intervention: Calcium hydroxide (Other)

Outcomes

Primary Outcomes

Clinical Success or Failure

Time Frame: 12 months

Incidence of pain, swelling, sinus tract formation, tenderness to percussion after specified time period after intervention

Radiographic Success or Failure

Time Frame: 12 months

Incidence of Periapical radiolucency or widening and Resorption

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Liaquat College of Medicine and Dentostry
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Naheed Najmi

Vice Principal and Registrar

Liaquat College of Medicine and Dentostry

Study Sites (1)

Loading locations...

Similar Trials

Efficacy of PRF and MTA as Compared to... | Clinical Trial